Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report

Leukemia Research Reports - Tập 5 - Trang 11-13 - 2016
Minoru Kojima1,2, Daisuke Ogiya1, Akifumi Ichiki1, Ryujiro Hara1, Jun Amaki1,2, Hidetsugu Kawai1, Hiroki Numata1, Ai Sato1, Mitsuki Miyamoto1, Rikio Suzuki1,3, Shinichiro Machida1, Hiromichi Matsushita4, Yoshiaki Ogawa1, Hiroshi Kawada1, Kiyoshi Ando1
1Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan
2Department of Hematology, Ebina General Hospital, Japan
3Division of Internal Medicine, Hadano Red Cross Hospital, Japan
4Department of Laboratory Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan

Tài liệu tham khảo

Ohno, 2003, Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate, Leukemia, 17, 1454, 10.1038/sj.leu.2403031 Shen, 1997, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood, 89, 3354, 10.1182/blood.V89.9.3354 Soignet, 2001, United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J. Clin. Oncol., 19, 3852, 10.1200/JCO.2001.19.18.3852 Tobita, 1997, Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid, Blood, 90, 967, 10.1182/blood.V90.3.967 Hashimoto, 1995, Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4, J. Cancer Res. Clin. Oncol., 121, 696, 10.1007/BF01218530 Lo-Coco, 2013, Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N. Engl. J. Med., 369, 111, 10.1056/NEJMoa1300874 Thirugnanam, 2009, Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen, Biol. Blood Marrow Transplant., 15, 1479, 10.1016/j.bbmt.2009.07.010 Gallagher, 2012, Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia, Blood, 120, 2098, 10.1182/blood-2012-01-407601 Côté, 2000, Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia, Blood, 96, 3200, 10.1182/blood.V96.9.3200 Goto, 2011, Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment, Blood, 118, 1600, 10.1182/blood-2011-01-329433